Sixteen CEOs and economists lay out a roadmap to revive the economy

Zydus Cadila, India's fourth-largest drug company by revenue, is banking big on research of new drugs, even though others have bowed out. Zydus expects the new drug business to grow to Rs 3,500 crore in four-five years

What differentiates business leaders who display high octane stamina and productivity from lesser mortals who also work long hours

As water gets increasingly scarce, companies see their future closely aligned with being water neutral or better still, water positive.

Pursue an interest other than work, and you could reap immediate and long-term gains.

By following the strategy of doing a few things well, V.C. Nannapaneni has helped Natco Pharma carve out a space for itself.

Adversity builds resilience. It also helped me discover my reason for being - which was to create a self-sustaining high-performance organisation.

Indian pharma companies are facing strong headwinds, but they are also exploring every new opportunity to ensure a quick recovery.

Leading Indian pharmaceutical companies are facing competition in the US from relatively smaller firms back home.

E-governance is the watchword in Andhra Pradesh and Telangana, both of which have launched unique digital initiatives.

Many major pharma stocks, seen as safe bets in the worst of times, have seen their market caps slip in the past year. Is pharma losing its sheen on the bourses?

Indian drug makers are slugging it out with Big Pharma over launch of biosimilars. Will they be able to hold their fort in this emerging space?

The deal, which cost Dr. Reddy's $350 million, translates into around $45 million paid for each product.

Till it starts getting approvals for new product launches in the US market, analysts see tough times continuing for Dr Reddy's, the Hyderabad-headquartered, NYSE-listed Indian pharma major.

\"Moves towards ensuring simplified procedures with time-bound accountability for approvals will go a long way in driving growth,\" says Dr Reddy's Laboratories Co-Chairman and CEO G.V. Prasad.

Many believe that it is pressure from a section of the US pharma giants who see their market shrinking that has prompted the USFDA's excessively suspicious approach towards them.

The profit for the second quarter period crossed Rs 700 crore. According to analysts, these were a good set of numbers given the challenges and the fact that it did not take any price hikes.

There is an awareness of the need for executive coaching, especially for business leaders in new roles. There is a realisation that mentoring is crucial, more so at the time of succession.

The SKS Microfinance founder, who had to unceremoniously exit in 2011, is giving final touches to the application for a small finance bank for his start-up VAYA Finserv.

Tata Consultancy Services (TCS) CEO N. Chandrasekaran said that the company decentralized aggressively during the economic meltdown of 2008/2009 as part of efforts to improve efficiency.